Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials

AIM: To examine the association between changes in lipids and markers of haemoconcentration (haematocrit and serum albumin) with empagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, in patients with type 2 diabetes (T2D) using pooled data from four phase 3 randomized trials. MATERIALS AND MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Lund, Søren S., Sattar, Naveed, Salsali, Afshin, Neubacher, Dietmar, Ginsberg, Henry N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290508/
https://www.ncbi.nlm.nih.gov/pubmed/34463415
http://dx.doi.org/10.1111/dom.14534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290508/
https://www.ncbi.nlm.nih.gov/pubmed/34463415
http://dx.doi.org/10.1111/dom.14534

Ejemplares similares